David 20peyton 20and 20rob 20jensen 20april 202011


DesignMedix, Inc develops drugs to overcome drug resistance in multiple diseases, and has a malaria drug ready for human trials, to be sponsored by the NIH.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Portland, OR, USA
  • Currency USD
  • Founded June 2008
  • Employees 4
  • Incorporation Type C-corp
  • Website designmedix.com

Company Summary

DesignMedix develops impactful disease cures that overcome drug resistance, a major threat to human health. Leveraging $3M in angel investment with over $12M in non-dilutive funding, DesignMedix has efficiently used angel investment to develop a novel malaria cure, ready for human safety trials to be sponsored by the NIH. Immediately upon FDA approval, the drug will be eligible for a tradable Priority Review Voucher. Recent PRV sales: $125-350M.


  • Default avatar
    Lynnor B Stevenson
    Board Chair

    Lynnor Stevenson, PhD, has 30 yrs experience bioscience startups. CEO of 4 bio companies including Heska (HSKA), and member of 10 founding teams for companies, 6 of which had successful exits by IPO. She was the founding CEO and a long time member of the Board of Directors of Heska Corporation, a public animal health company that develops drugs, vaccines and diagnostics.

  • Default avatar
    Sandra L Shotwell

    Sandra Shotwell, PhD, has 20 yrs experience in technology commercialization and startups, including 3 yrs as Head of Licensing, NIH. Experience includes negotiating license and research partnerships with large pharmaceutical companies, and founding and serving as a board member for start-up companies. She also is a nationally-recognized authority on the role of intellectual property in the development of drugs for neglected diseases.

  • Default avatar
    David H Peyton

    David Peyton, PhD., is co-inventor of DM technology. He has been working on medicinal chemistry of malaria for more than a decade and brings over two decades of organic, physical, and analytical chemistry experience. He is a Professor of Chemistry at Portland State University.

  • Default avatar
    James Wilson

    James Wilson, M.S. is a senior executive with more than 20 years experience in providing clinical trial services to the biopharmaceutical industries. He joined Clinimetrics in 1989 and served as co-principal, growing the company entirely through retained earnings to more than 350 world-wide employees prior to being acquired by fortune 500
    company, Omnicare. He is an active angel investor.

  • Default avatar
    Erik Iverson

    Erik Iverson is EVP, Business Development at the Infectious Disease Research Institute (IDRI) Seattle, Wa, a global health research institute developing diagnostics, vaccines, and treatments for neglected diseases of poverty. Prior to joining IDRI, he was Associate General Counsel at the Bill & Melinda Gates Foundation where he led development and implementation of the Foundation’s Global Access policy through grants and strategic initiatives.

Previous Investors

  • Default avatar
    Oregon Angel Fund
    Default avatar
    Private Angel Investors
  • Default avatar
    Portland Seed Fund